Serum CA125 and PSA concentrations in patients with lymphoma

Clinical Advances in Hematology and Oncology

Volumn 6, Issue 7, 2008, Pages 527-531

  Wiernik, Peter H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

CA125 PSA; Non hodgkin lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; NBR1 PROTEIN, HUMAN; PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PERITONEAL DISEASE; PLEURA EFFUSION; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; BLOOD; FEMALE; HEART TUMOR; MALE; METASTASIS; OVARY TUMOR; PERITONEUM TUMOR; PROSTATE TUMOR;

FEMALE; HEART NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; OVARIAN NEOPLASMS; PERICARDIAL EFFUSION; PERITONEAL NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEINS;

EID: 52149108482     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Kenemans P, Bast R, Yedima C, Price M, Hilgers J. CA125 and polymorphic epithelial mucin as serum tumor markers. Cancer Rev. 1988;11:119-144.
2. Zeillemaker AM, Verbrugh HA, Hoynck van Papendrecht AAGM, Leguit P. CA125 secretion by peritoneal mesothelial cells. J Clin Pathol. 1994;47:263-265.
3. Bischof P. What do we know about the origin of CA125? Eur J Obstet Gynecol Reprod Biol. 1993;49:93-98.
4. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Clovin RB, Knapp BC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-1337.
5. Bairey O, Blickstein D, Stark P, et al. Serum CA125 as a prognostic factor in non-Hodgkins lymphoma. Leuk Lymphoma. 2003;44:1733-1738.
6. Bast RC Jr, King TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
7. Halila H, Stenman UH, Seppala M. Ovarian cancer antigen CA125 levels in pelvic inflammatory disease and pregnancy. Cancer. 1986;57:1327-1329.
8. Bergmann JF, Bidart JM, George M, Beaugrand M, Levy VG, Bohuon C. Elevation of CA125 in patients with benign and malignant ascites. Cancer. 1987;59:213-217.
9. Grankvist K, Ljungberg B, Rasmuson T. Evaluation of five glycoprotein tumor markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for prognosis of renal-cell carcinoma. Int J Cancer. 1997;74:233-236.
10. Salgia R, Harpole D, Herndon JE, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA125 and CEA in non-small cell lung cancer. Anticancer Res. 2001;21:1241-1246.
11. Norum LF, Erikstein B, Nustad K. Elevated CA125 in breast cancer-a sign of advanced disease. Tumour Biol. 2001;22:223-228.
12. Nakata B. Hirakawa S, Chung K, et al. Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 1998; 83;2488-2492.
13. Birgen D, Ertem U, Duru F, et al. Serum CA125 levels in children with acute leukemia and lymphoma. Leuk Lymphoma. 2005;46:1177-1181.
14. Benboubker L, Valat C, Linassier C, et al. A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels. Ann Oncol. 2000;11:1485-1491.
15. Dilek L, Ayakta H, Demir C. Meral C, Ozturk M. CA125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol. 2005;27:51-55.
16. Batlle M, Ribera J-M, Oriol A, et al. Usefulness of tumor markers CA125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: a study of 200 patients. Leuk Lymphoma. 2005;46:1471-1476.
17. Wei G, Yuping Z, Jun W, Bing Y, Qiaohua Z. CA125 expression in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2006;47:1322-1326.
18. Russo F, Lastoria S, Svanera G, et al. Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma. Leak Lymphoma. 2007;48:723-730.
19. Bonnet C, Beguin Y, Fassotte M-F, Seidel L, Luyckx F, Fillet G. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma. Eur J Haematol. 2007;78:399, 404.
20. Spitzer M, Kaushal N, Benjamin F, Maternal CA125 levels in pregnancy and the puerperium. J Reprod Med. 1998;43:387-392.
21. Sevinc A, Buyukberber S, Sari R, Kiroglu Y, Turk HM, Ates M. Elevated serum CA-125 levels in hemodialysis patients with peritoneal or pericardial fluids. Gynecol Oncol. 2000;77:254-257.
22. Koksal Y, Caliskan U, Ucar C, Reisli I. A case of primary ovarian lymphoma in a child with high levels of CA125 and CA19-9. Pediatr Hematol Oncol. 2005; 27:594-595.
23. Kuroda H, Kida M, Watanabe H, Shirao S, Konda K. Serum CA125 level associated with disease activity in a patient with follicular lymphoma. Rinsho Ketsueki. 2005;46:281-283.
24. Antonarakis ES, Fradin JM, Petronis JD, Couzi RJ. Not what it seems. Am J Med. 2007;120:408-411.
25. Watanabe M, Kanda T, Takatama M, et al. An autopsy case of malignant lymphoma with high serum CA125 level occurring only in the brain and pericardium. J Med. 1996;27:221-227.
26. Cauney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its rule as a tumour marker. Br J Cancer. 1984;50:765-769.
27. Liu CJ, Tzeng CH, Liu JH, et al. CA125 in non-Hodgkin's lymphoma. Zhonghua Yi Xue Za Zhi. 1991;48:382-387.
28. Lazzarino M, Oriandi E, Klersy C, et al. Serum CA125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity. Cancer. 1998;82:576-582.
29. Zidan J, Hussein O, Basher W, Zohar S. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist. 2004;9:417-421.
30. Acin P, Besses C, Centelles M, Machengs I, Sans-Sabrafen J. Elevated serum CA125 tumor market in chronic lymphocytic leukemia with mesothelial involvement. Am J Hematol. 1996;53:281.
31. Bairey O, Shaklai M. Serum CA125 levels in patients with chronic lymphocytic leukemia. Clin Lab Haematol. 2005;27:57-60.
32. Iwasaki T, Hamano T, Aizawa K, Kobayashi K, Kakishita E. Increased serum CA125 levels in plasma cell dyscrasias. Acta Haematol. 1997;98:104-108.
33. Diamandis EP, Yu H, Sutherland DJ. Detection of prostate=specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat. 1994;32:301-310.
34. Borchert GH, Melegos DN, Tomlinson G, et al. Molecular forms of prostate-specific antigen in the serum of woman with benign and malignant breast diseases. Br J Cancer. 1997;76:1087-1094.
35. Rae F, Bulmer B, Nicol D, Clements J. The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. Immunopharmacology. 1999;45:63-68.
36. Pummer K, Wirnsberger G, Purstner P, Stettner H, Wandschneider G. False positive prostate specific antigen values in the sera of women with renal cell carcinoma. J Urol. 1992;148:21-23.
37. Djavan B, Keffer JH, Molberg K, Roehrborn CG. False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. Urology. 1995;45:875-878.
38. Kato H, Kinoshita T, Suzuki S, et al. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: correlation with extent of IL-6 expression and serum concentration. Br J Haematol. 1996;92:1014-1021.
39. Lin DL, Whitney MC, Yao Z, Keller ET. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res. 2001;7:1773-1781.
40. Johnson TR, Barber DB, Teichman JM, Able AC. T-cell lymphocytic lymphoma involving the prostate presenting as elevated PSA in paraplegia: case report. J Spinal Cord Med. 1996;19:258-260.
41. Eisenberger CF, Walsh PC, Eisenberger MA, et al. Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. Urology. 1999;53:175-179.
42. Terris MK, Hausdorff J, Freiha FS. Hematolymphoid malignancies diagnosed at the time of radical prostatectomy. J Urol. 1997;158:1457-1459.
43. Drinis S, Finkelstein MP, Torrorelis DG, Konno S, Choudhury MS. Five-year prognosis after radical prostatectomy in a patient with localized prostate cancer and incidental non-Hodgkin's lymphoma. Urol Int. 2001;66:105-107.
44. Kunthur A, Wiernik PH, Dutcher JP. Renal parenchymal tumors and lymphoma in the same patient: a case series and review of the literature. Am J Hematol. 2006;81:271-280.
45. Hamaloglu E, Topaloglu S, Ozdemir A, Ozenc A. Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: a review of the literature. World J Gastroenterol. 2006;12:3564-3574.
46. Wiernik PH, Hu X, Ratech H, Finebertg S, Etkind P, Walewski JA. Non-Hodgkin's lymphoma in women with breast cancer. Cancer J. 2000;6:336-342.
47. Nishiu M, Yanagawa R, Nakatsuka S, et al. Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: identification of genes related to disease progression. Jpn J Cancer Res. 2002;93:894-901.
48. Ballario R, Beltrami P, Cavalleri S, Ruggera L, Zorzi MG, Artibani W. An unusual pathological finding of chronic lymphocytic leukemia and adenocarcinoma of the prostate after transurethral resection for complete urinary retention: case report. BMC Cancer. 2004;4:95.
49. Mattos dos Santos R, Aparecida Rainho C, Carlos Souza Trindade J, Carlos Souza Trindade Filho J, Lauro Viana de Camargo J, Regina Rogatto S. Genotyping of AR and PSA polymorphisms in a patient with Klinefelter syndrome, non-Hodgkin lymphoma, and adenocarcinoma of the prostate. Cancer Genet Cytogenet. 2004;153:165-169.
50. Oosterheert JJ, Budel LM, Vos P, Wittebol S. High levels of serum prostate-specific antigen due to PSA producing follicular non-Hodgkin's lymphoma. Eur J Haematol. 2007;79:155-158.